Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - tobramycin - solution for injection - tobramycin 40 mg/ml - antibacterials for systemic use

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - tobramycin - solution for injection - tobramycin 40 mg/ml - antibacterials for systemic use

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - tobramycin - solution for injection - tobramycin 40 mg/ml - antibacterials for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - tobramycin - solution for injection - 40 milligram(s)/millilitre - other aminoglycosides; tobramycin

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - tobramycin - solution for injection - 40 micromol - other aminoglycosides

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - tobramycin, quantity: 40 mg - injection, solution - excipient ingredients: disodium edetate; phenol; sodium metabisulfite; sulfuric acid; sodium hydroxide; water for injections - nebcin is indicated for the treatment of the following serious infections caused by susceptible micro-organisms: central nervous system infections, including meningitis, septicaemia and neonatal sepsis; gastrointestinal infections, including peritonitis; and other such significant infections as: complicated and recurrent urinary tract infections, such as pyelonephritis and cystitis; lower respiratory tract infections, including pneumonia, bronchopneumonia, and acute bronchitis; skin, bone and soft-tissue infections, including burns. aminoglycosides, including nebcin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. nebcin may be considered in serious staphylococcal infections for which penicillin or other less potentially toxic drugs are contraindicated, and when bacterial susceptibility testing and clinical judgement indicate its use. bacterial cultures should be obtained prior to and during treatment to isolate and identify aetiologic organisms and to test their susceptibility to nebcin. if susceptibility tests show that the causative organism is resistant to nebcin, other appropriate therapy should be instituted. in patients in whom gram-negative septicaemia, neonatal sepsis, or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, nebcin therapy may be initiated before results of susceptibility studies are obtained. the decision to continue nebcin therapy should be based upon the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed under warnings.

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 5 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; nicotinamide, quantity: 50 mg/ml; dexpanthenol, quantity: 10 mg/ml; pyridoxine hydrochloride, quantity: 25 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. patients requiring parenteral b vitamin therapy who cannot tolerate intramuscular injections. 5. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that iv b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 6. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2 and b6. 7. peripheral neuritis caused by vari

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 10 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; pyridoxine hydrochloride, quantity: 5 mg/ml; dexpanthenol, quantity: 2.5 mg/ml; nicotinamide, quantity: 25 mg/ml; cyanocobalamin, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. commonly, several b vitamin deficiencies may occur similtaneously. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: glycerol; phenol; metacresol; zinc; dibasic sodium phosphate dihydrate; arginine; hydrochloric acid; sodium hydroxide; water for injections; nicotinamide - treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.